Harvest Fund Management Co. Ltd Acquires 6,854 Shares of Boston Scientific Co. (NYSE:BSX)

Harvest Fund Management Co. Ltd increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 94.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,126 shares of the medical equipment provider's stock after purchasing an additional 6,854 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in Boston Scientific were worth $1,262,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of Boston Scientific by 2.3% during the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after acquiring an additional 1,389,172 shares during the period. Wellington Management Group LLP raised its position in Boston Scientific by 2.2% during the third quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock valued at $2,750,385,000 after purchasing an additional 718,515 shares in the last quarter. Geode Capital Management LLC lifted its stake in Boston Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock worth $2,469,607,000 after purchasing an additional 480,729 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Boston Scientific by 5.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,475,031 shares of the medical equipment provider's stock valued at $756,990,000 after purchasing an additional 456,654 shares in the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Boston Scientific by 21.6% in the 4th quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock valued at $518,138,000 after purchasing an additional 1,028,977 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Boston Scientific Trading Up 2.0 %

BSX traded up $2.05 during trading on Monday, reaching $102.74. 5,830,086 shares of the stock traded hands, compared to its average volume of 5,772,588. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock's 50-day moving average is $101.68 and its 200 day moving average is $92.50. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17. The stock has a market capitalization of $151.96 billion, a PE ratio of 82.19, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock valued at $14,319,269 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on BSX. Wells Fargo & Company raised their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Raymond James raised their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Citigroup upped their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, TD Cowen upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.